Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

642
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
642
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

1.1K
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
1.1K
Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

1.1K
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
1.1K
Antipsychotic Drugs: Therapeutic Uses and Side Effects01:21

Antipsychotic Drugs: Therapeutic Uses and Side Effects

989
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
989
Drug Therapy01:28

Drug Therapy

331
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
331
Schizophrenia01:17

Schizophrenia

1.3K
Schizophrenia, a term introduced by Swiss psychiatrist Eugen Bleuler in 1911, describes a severe psychological disorder marked by profound disruptions in attention, thought processes, language, emotion, and interpersonal relationships. The core feature of schizophrenia is psychosis — a state characterized by a fundamental detachment from reality. This disconnection manifests through distorted logic, impaired perception, and atypical behavior, severely affecting the lives of those...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial: Advances in the neurobiology and neuropsychology of offending behaviour.

Frontiers in psychiatry·2026
Same author

Pharmacological interventions for co-occurring psychopathology in people with borderline personality disorder: secondary analysis of the Cochrane systematic review with meta-analyses.

The British journal of psychiatry : the journal of mental science·2024
Same author

Pharmacological interventions for people with borderline personality disorder.

The Cochrane database of systematic reviews·2022
Same author

Psychotherapies for borderline personality disorder: a focused systematic review and meta-analysis.

The British journal of psychiatry : the journal of mental science·2022
Same author

Psychological interventions for antisocial personality disorder.

The Cochrane database of systematic reviews·2020
Same author

Pharmacological interventions for antisocial personality disorder.

The Cochrane database of systematic reviews·2020

Related Experiment Video

Updated: Feb 28, 2026

Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans
07:35

Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans

Published on: February 4, 2014

12.0K

Clozapine dose for schizophrenia.

Selvizhi Subramanian1, Birgit A Völlm, Nick Huband

  • 1Department of Psychiatry, Morecambe Community Mental Health Team, Victoria House, Thornton RD, Morecambe, UK, LA4 5NN.

The Cochrane Database of Systematic Reviews
|June 15, 2017
PubMed
Summary
This summary is machine-generated.

This review found no significant differences in mental state improvements between various clozapine doses for schizophrenia. Lower doses may reduce adverse effects like weight gain and lethargy, but more research is needed.

More Related Videos

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
05:14

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

4.7K
Development of a Virtual Reality Assessment of Everyday Living Skills
10:32

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

19.4K

Related Experiment Videos

Last Updated: Feb 28, 2026

Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans
07:35

Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans

Published on: February 4, 2014

12.0K
Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
05:14

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

4.7K
Development of a Virtual Reality Assessment of Everyday Living Skills
10:32

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

19.4K

Area of Science:

  • Psychiatry and Pharmacology
  • Clinical Trial Analysis

Background:

  • Schizophrenia and related disorders are severe mental illnesses impacting cognition, emotion, and behavior.
  • Clozapine is a crucial treatment for schizophrenia, especially treatment-resistant cases, improving positive and negative symptoms.
  • Optimal clozapine dosage for balancing efficacy and side effects remains unclear.

Purpose of the Study:

  • To compare the efficacy and tolerability of clozapine at different doses.
  • To identify the optimal clozapine dose for treating schizophrenia, schizophreniform, and schizoaffective disorders.

Main Methods:

  • Systematic search of the Cochrane Schizophrenia Group's Study-Based Register of Trials up to December 2016.
  • Inclusion of all relevant randomized controlled trials (RCTs) comparing different clozapine doses in patients with schizophrenia spectrum disorders.
  • Data analysis using random-effects models for dichotomous and continuous outcomes, with risk of bias and GRADE assessments.

Main Results:

  • Five studies were included, comparing very low (≤149 mg/day), low (150-300 mg/day), and standard (301-600 mg/day) clozapine doses.
  • No significant differences in mental state improvement (BPRS-A scores) were found between very low, low, and standard doses.
  • Limited evidence suggests lower incidence of adverse effects (e.g., lethargy, hypersalivation, dizziness, tachycardia) and less weight gain at lower clozapine doses compared to standard doses.

Conclusions:

  • No definitive evidence supports specific dose-response relationships for mental state improvement with clozapine.
  • Lower clozapine doses may be associated with fewer adverse effects and less weight gain.
  • High-quality evidence is limited, necessitating further research on optimal dosing, long-term outcomes, and higher dose regimens.